Alopecia Areata(AA)
7
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata
Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata